REGN - Regeneron Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
395.22
-3.84 (-0.96%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close399.06
Open399.90
Bid348.34 x 800
Ask578.00 x 1100
Day's Range390.00 - 399.90
52 Week Range281.89 - 437.90
Volume485,114
Avg. Volume686,307
Market Cap42.662B
Beta (3Y Monthly)1.72
PE Ratio (TTM)28.70
EPS (TTM)13.77
Earnings DateNov 6, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est408.33
Trade prices are not sourced from all markets
  • Why the Earnings Surprise Streak Could Continue for Regeneron (REGN)
    Zacks19 hours ago

    Why the Earnings Surprise Streak Could Continue for Regeneron (REGN)

    Regeneron (REGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

  • Regeneron's Dupixent Meets Goals in Nasal Polyps Studies
    Zacks2 days ago

    Regeneron's Dupixent Meets Goals in Nasal Polyps Studies

    Regeneron's (REGN) atopic dermatitis drug, Dupixent meets goals in two late-stage studies for nasal polyps.

  • 4 Strong Stocks to Buy That Double As Big Takeover Targets
    InvestorPlace3 days ago

    4 Strong Stocks to Buy That Double As Big Takeover Targets

    One of the quickest ways to make money in the stock market is through M&A. Acquisition premiums are usually in excess of 20%, so if you own stock in a company and that company gets acquired, you could easily make 20% or more in a day. The potential rewards from takeover stocks are compelling.

  • PR Newswire3 days ago

    Dupixent® (dupilumab) showed positive topline results in two Phase 3 trials of patients with chronic rhinosinusitis with nasal polyps

    PARIS and TARRYTOWN, N.Y., Oct. 16, 2018 /PRNewswire/ -- Two pivotal Phase 3 placebo-controlled trials evaluating Dupixent® (dupilumab) in adults with inadequately-controlled chronic rhinosinusitis with nasal polyps ("CRSwNP") met all primary and secondary endpoints.

  • Reuters3 days ago

    Sanofi, Regeneron say late-stage Dupixent trials show positive results

    Drugmakers Sanofi and Regeneron said on Tuesday that they received positive results for their Dupixent product, which treats eczema and is seen as a key driver of future revenues. Sanofi and Regeneron ...

  • GlobeNewswire3 days ago

    Sanofi: Dupixent® (dupilumab) showed positive topline results in two Phase 3 trials of patients with chronic rhinosinusitis with nasal polyps

    Dupixent ® (dupilumab) showed positive topline results in two Phase 3 trials of patients with chronic rhinosinusitis with nasal polyps Dupixent significantly reduced nasal polyp size, nasal congestion ...

  • PR Newswire3 days ago

    Dupixent® (dupilumab) Showed Positive Topline Results in Two Phase 3 Trials of Patients with Chronic Rhinosinusitis with Nasal Polyps

    Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that both pivotal Phase 3 placebo-controlled trials evaluating Dupixent® (dupilumab) in adults with inadequately-controlled chronic rhinosinusitis with nasal polyps ("CRSwNP"), met all their primary and secondary endpoints.

  • 5 Healthcare Stocks to Buy for Complete Portfolio Wellness
    InvestorPlace9 days ago

    5 Healthcare Stocks to Buy for Complete Portfolio Wellness

    Figuring out which healthcare stocks to buy has never been an easy task. President Trump has repeatedly blasted the Affordable Care Act, promising to overhaul our healthcare system. Naturally, many healthcare stocks have experienced a tumultuous ride in the markets under the Trump White House.

  • How To Trade Growth Stocks: The Easy Way To Check And Confirm Institutional Support
    Investor's Business Daily10 days ago

    How To Trade Growth Stocks: The Easy Way To Check And Confirm Institutional Support

    The concept of support is not one of the first things you need to understand as an investor, but you will find it a powerful tool once you learn to use it.

  • InvestorPlace10 days ago

    ARWR Stock Sinks After Signing a Big Collaboration Deal

    On the charts, Arrowhead Pharmaceuticals (NASDAQ: ARWR) showed a “double top,” touching around $20 twice between September and October, before crashing down more than 30% in the last week. As value investors will ask after such a drop…what happened? On Oct. 4, Arrowhead announced that it entered into a license and collaboration with Janssen Pharmaceuticals, a unit of Johnson & Johnson (NYSE: JNJ).

  • PR Newswire10 days ago

    Libtayo® (cemiplimab-rwlc) Data at ESMO 2018 Congress Provide New Insights in Six Tumor Types Under Investigation

    TARRYTOWN, N.Y. and PARIS, Oct. 8, 2018 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi will present a diverse set of data from their joint clinical program investigating Libtayo® (cemiplimab-rwlc) at the ESMO 2018 Congress (European Society for Medical Oncology) from October 19 to 23 in Munich, Germany. Libtayo is a fully-human monoclonal antibody targeting the immune checkpoint receptor PD-1 (programmed cell death protein-1).

  • 3 Top Biotech Stocks to Buy in October
    Motley Fool10 days ago

    3 Top Biotech Stocks to Buy in October

    Adding these biotech stocks to growth portfolios this month could prove to be profit-friendly.

  • PR Newswire11 days ago

    Regeneron to Report Third Quarter 2018 Financial and Operating Results and Host Conference Call and Webcast on November 6, 2018

    TARRYTOWN, N.Y. , Oct. 8, 2018 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) today announced that it will report its third quarter 2018 financial and operating results on Tuesday, November ...

  • Simply Wall St.14 days ago

    Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Financial Strength Analysis

    With a market capitalization of US$43.5b, Regeneron Pharmaceuticals Inc (NASDAQ:REGN) is a large-cap stock, which is considered by most investors as a safe bet. Common characteristics for these big stocks Read More...

  • Biotech Stock Roundup: ALXN on Acquisition Spree, FDA Nod for REGN, AMGN Drugs
    Zacks16 days ago

    Biotech Stock Roundup: ALXN on Acquisition Spree, FDA Nod for REGN, AMGN Drugs

    The biotech sector grabs headlines this week with FDA approvals plus licensing and acquisition pacts.

  • Ionis Pharmaceuticals’ Valuations on September 28
    Market Realist16 days ago

    Ionis Pharmaceuticals’ Valuations on September 28

    Ionis Pharmaceuticals (IONS) develops drugs for life-threatening diseases, and it commercializes the approved products in collaboration with other pharmaceutical companies. Ionis reported revenues of $118.0 million during the second quarter for 5.0% growth in YoY (year-over-year) revenues compared to the second quarter of 2017.

  • Sanofi/Regeneron's Cemiplimab Wins FDA Nod for Skin Cancer
    Zacks18 days ago

    Sanofi/Regeneron's Cemiplimab Wins FDA Nod for Skin Cancer

    Sanofi (SNY)/Regeneron's (REGN) anti- PD-1 drug cemiplimab wins FDA approval for a type of skin cancer.

  • Sanofi’s Dupixent: Growth Prospects and Phase 3 Trials
    Market Realist18 days ago

    Sanofi’s Dupixent: Growth Prospects and Phase 3 Trials

    Sanofi (SNY) develops Dupixent in collaboration with Regeneron Pharmaceuticals (REGN). It’s currently approved for moderate-to-severe atopic dermatitis in adults. The drug is undergoing multiple late-stage trials for various other indications, which, if approved, could expand Sanofi’s market opportunities and growth potential for Dupixent.

  • Sanofi Eyes Market Expansion with Phase 3 Data for Dupixent
    Market Realist18 days ago

    Sanofi Eyes Market Expansion with Phase 3 Data for Dupixent

    Sanofi’s (SNY) Dupixent (dupilumab) is an interleukin-3 and interleukin-4 inhibitor that helps lower moderate-to-severe atopic dermatitis. It’s jointly developed by Sanofi and Regeneron (REGN). On September 15, Sanofi and Regeneron announced Phase 3 data results for Dupixent for the treatment of moderate-to-severe atopic dermatitis in adolescents aged 12 to 17 years.

  • Reuters20 days ago

    Sanofi, Regeneron skin cancer drug gets FDA nod

    Sanofi SA said on Friday its skin cancer drug, made in partnership with Regeneron Pharmaceuticals Inc, was approved by the U.S. Food and Drug Administration. The drug, Libtayo, is used to treat a rare form of skin cancer, in patients whose condition has not improved following surgery or chemotherapy. Metastatic cutaneous squamous cell carcinoma is the second-most common form of skin cancer, which accounts for an estimated 7,000 deaths in the United States each year, Sanofi said.

  • Regeneron, Sanofi Win Approval for First Immuno-Oncology Drug
    Bloomberg20 days ago

    Regeneron, Sanofi Win Approval for First Immuno-Oncology Drug

    Regeneron Pharmaceuticals Inc. and Sanofi won U.S. Food and Drug Administration approval for their first immuno-oncology drug, a therapy that the companies hope will jump-start their cancer joint venture. Libtayo, also known as cemiplimab, treats a deadly form of skin cancer. It’s the first drug to come out of the companies’ 2015 partnership to research therapies that use the body’s immune system to fight various malignancies.

  • MarketWatch21 days ago

    Sanofi, Regeneron have skin-cancer drug approved

    Sanofi and Regeneron Pharmaceuticals Inc. said late Friday the U.S. Food and Drug Administration has approved their drug Libtayo for the treatment of a common type of metastatic skin cancers that previously had no treatment. The medication was on priority review. Both companies will market the drug in the U.S. Shares of Regeneron rose 2% after the announcement, while the American depositary shares of Sanofi were flat in the extended session Friday.

  • FDA approves Libtayo® (cemiplimab-rwlc) as first and only treatment for advanced cutaneous squamous cell carcinoma
    PR Newswire21 days ago

    FDA approves Libtayo® (cemiplimab-rwlc) as first and only treatment for advanced cutaneous squamous cell carcinoma

    * CSCC is the second most common skin cancer in the U.S. PARIS AND TARRYTOWN, N.Y., Sept. 28, 2018 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has approved Libtayo® (cemiplimab-rwlc) for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are not candidates for curative surgery or curative radiation. Libtayo is a fully-human monoclonal antibody targeting the immune checkpoint receptor PD-1 (programmed cell death protein-1) and is the first and only treatment specifically approved and available for advanced CSCC in the U.S.

  • PR Newswire21 days ago

    FDA Approves Libtayo® (cemiplimab-rwlc) as First and Only Treatment for Advanced Cutaneous Squamous Cell Carcinoma

    CSCC is the second most common skin cancer in the U.S. Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved Libtayo® (cemiplimab-rwlc) for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are not candidates for curative surgery or curative radiation. Libtayo is a fully-human monoclonal antibody targeting the immune checkpoint receptor PD-1 (programmed cell death protein-1) and is the first and only treatment specifically approved and available for advanced CSCC in the U.S.

  • Drugmakers are finding new solutions to food allergies
    CNBC Videos18 days ago

    Drugmakers are finding new solutions to food allergies

    CNBC's Meg Tirrell reports on what some drug companies are doing to fight increasing rates of food allergies in children.